This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2020 Aug 1;396(10247):311.

doi: 10.1016/S0140-6736(20)30545-6.

Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER

Eoin D O'Sullivan¹, Iain M MacIntyre²

Affiliations

Affiliations

¹ Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK. Electronic address: eoin.osullivan@ed.ac.uk.
² Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.

PMID: 32738951
DOI: 10.1016/S0140-6736(20)30545-6

Comment

Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER

Eoin D O'Sullivan et al. Lancet. 2020.

. 2020 Aug 1;396(10247):311.

doi: 10.1016/S0140-6736(20)30545-6.

Authors

Eoin D O'Sullivan¹, Iain M MacIntyre²

Affiliations

¹ Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK. Electronic address: eoin.osullivan@ed.ac.uk.
² Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.

PMID: 32738951
DOI: 10.1016/S0140-6736(20)30545-6

No abstract available

PubMed Disclaimer

Comment in

Individual patient risk assessment and cost-benefit analysis of patiromer in AMBER - Authors' reply.
Agarwal R, Rossignol P, White WB, Williams B. Agarwal R, et al. Lancet. 2020 Aug 1;396(10247):311-312. doi: 10.1016/S0140-6736(20)30534-1. Lancet. 2020. PMID: 32738950 No abstract available.

Comment on

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, Ma J, White WB, Williams B. Agarwal R, et al. Lancet. 2019 Oct 26;394(10208):1540-1550. doi: 10.1016/S0140-6736(19)32135-X. Epub 2019 Sep 15. Lancet. 2019. PMID: 31533906 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information